ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy
Despite the promise of immunotherapy for gastric adenocarcinoma, choices for the selection of effective antigenic targets are very limited. Previously published data and our own in-house computational analysis have suggested that ANTXR1 is a potential target, simultaneously expressed in malignant tumor cells and the endothelial cells of the tumors. However, the expression pattern of ANTXR1 protein in clinical samples of gastric adenocarcinoma has not been fully evaluated.
Using immunohistochemistry (IHC), we recorded the percentage of ANTXR1 positive cells separately in tumor cells and endothelial cells in the primary tumor, non-tumor gastric tissue adjacent to the primary tumor, and tumor in metastatic sites of 140 gastric adenocarcinoma patients. We also evaluated the association of ANTXR1 expression with the Lauren histological classification of the primary tumors, the patient’s history of neoadjuvant chemotherapy and/or radiotherapy, and the patient’s overall survival.
ANTXR1 was expressed in a mean of 73.89 ± 30.12% of tumor cells and 13.55 ± 20.53% of endothelial cells in the primary tumors. Intestinal adenocarcinomas had lower ANTXR1 expression in the tumor cells and higher ANTXR1 expression in the endothelial cells of the tumor regions, and a history of neoadjuvant therapy was associated with increased ANTXR1 expression in the endothelial cells of the tumor regions. Finally, above median expression of ANTXR1 in the tumor cells of the tumor regions was associated with significantly lower overall patient survival.
Our findings suggest that ANTXR1 is a promising candidate for preclinical and clinical evaluation for gastric adenocarcinoma immunotherapy.
KeywordsChimeric antigen receptor T cell Gastric adenocarcinoma ANTXR1 TEM8 Antigenic targets Immunotherapy
ANTXR cell adhesion molecule 1
- CAR T cell
Chimeric antigen receptor T cells
Erb-b2 receptor tyrosine kinase 2
Kinase insert domain receptor
Programmed cell death 1
MS, NA, and MN designed the study; MS and BS performed the IHC evaluations; RS performed the statistical data analyses; and MN and SMD prepared the manuscript.
This project was funded by Tehran University of Medical Sciences, Digestive Disease Research Institute grant number 38435-37-02-97.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
This study was performed after the approval of Institutional Review Board of Tehran University of Medical Sciences (approval ID: IR.TUMS.DDRI.REC.1397.007).
Informed consent was obtained from all patients at the time of surgery for the use of their paraffin-embedded tissue blocks in research after finalizing their diagnostic procedure.
- 1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 68(6):394–424Google Scholar
- 5.Bang Y-J, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697CrossRefGoogle Scholar
- 8.National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines in oncology, gastric cancer, (Version 2.2018). https://www.nccn.org/professionals/physician_gls/default.aspx#gastric. Accessed 22 May 2018
- 16.Abcam IHC-PARAFFIN PROTOCOL (IHC-P). https://www.abcam.com/ps/pdf/protocols/ihc_p.pdf. Accessed 13 Nov 2017
- 21.Gutwein LG, Al-Quran SZ, Fernando S, Fletcher BS, Copeland EM, Grobmyer SR (2011) Tumor endothelial marker 8 expression in triple-negative breast cancer. Anticancer Res 31:3417–3422Google Scholar
- 22.Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, Croix BS (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61:6649–6655Google Scholar
- 24.Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235CrossRefGoogle Scholar